CD274 and triple-negative breast carcinoma: Slightly fewer triple negative breast cancer (TNBC) patients with mILC received anti-PD-L1 guided therapy after 2019 as compared to TNBC patients with mIDC (n = 4, 20.0% vs. n = 27, 32.9%).